← All research

Holidays, Restaurants and Vacations on a GLP-1: 10 Questions

Last verified May 2026 · 10 questions · 19 PubMed citations

Questions taken from r/Zepbound, r/Wegovy, r/Semaglutide, r/Mounjaro, r/Ozempic

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Two different things get called holiday problems here. One is arithmetic — whether a big day or a bad week undoes months of progress, and the answer is reliably no. The other is physiology: your stomach empties slower, you fill up sooner, and eating the way you used to eat now has consequences it did not have before. ★ The practical answers are about the second. ⛔ Where a genuine safety issue exists, it is flagged as one rather than folded into general advice — heavy drinking and repeatedly eating past fullness are not the same category of risk as a large plate. ⚠ And where the honest answer is that the trials never asked the question, we say that instead of inventing a number.

Questions and answers

Q1.Will one huge meal undo a month of progress?

★ No — and the general-population data are worth knowing because they are less generous than people expect in the other direction. A classic NIH cohort followed adults across the six weeks spanning Thanksgiving and Christmas and found an average gain of about 0.37 kg, with the heaviest-gaining subset around 2.3 kg. A larger three-country study using daily connected-scale data found average weight rising roughly 0.4-0.6 kg in the ten days after Thanksgiving, and most of that gain still there months later. ⚠ So the season adds weight in people generally, and it sticks — but that is a season, not a meal. ★ On treatment, the trial curves absorb single high-calorie days without deflecting; the long arc is set by what happens across weeks. ⛔ The thing actually worth avoiding on the day is not the calories. It is eating far past a fullness signal that is now much stronger, which is a vomiting and discomfort problem rather than a weight one.

Source thread ↗PMID 10727591PMID 27653588PMID 33567185PMID 35658024

Q2.Should I start my first dose right before a big holiday?

⛔ No, and this is one of the few genuinely bad ideas on this page. The first injection produces the sharpest acute drop in gastric emptying — pharmacology studies in obesity cohorts put the first-hour delay somewhere in the region of 30 to 70% — and nausea, vomiting and fullness peak during the early titration weeks in both major trial programs. ⚠ Putting that first dose within days of a 3,000-to-5,000-calorie meal is close to a worst case: high odds of vomiting, prolonged fullness and acute reflux, in a setting where you least want any of it. ★ There is a second, less-discussed problem in the same direction. A starter dose can blunt appetite so thoroughly that people cannot eat a meal they had genuinely looked forward to — which is a real loss even though it sounds like a good outcome. ★ Start a week or two after, not before.

Source thread ↗PMID 28941314PMID 32077010PMID 33567185PMID 35658024

Q3.Is a buffet still worth the money?

★ Almost certainly not, and the economics stop working before the enjoyment does. Total capacity falls sharply: these drugs slow emptying and produce earlier, stronger satiety after small portions, and in the trial programs daily energy intake fell by roughly 30-35% at maintenance doses — driven mostly by smaller meals rather than fewer of them. ⚠ The commonly reported experience matches: full after about one plate to one and a half, against three or four before. ⛔ The important part is what happens if you push past that. Repeatedly overriding a fullness signal to get value from a buffet is how people end up vomiting, and it is the behavior most likely to turn an ordinary side effect into a memorable one. ★ Order from a menu instead of paying by the plateful. The pricing model and your physiology are now working against each other.

Source thread ↗PMID 28941314PMID 32077010PMID 33567185PMID 35658024

Q4.How do I eat out without wasting food or feeling ill?

★ Assume the portion is roughly double what you can now finish, and plan for that before it arrives rather than after. Emptying studies put the first-hour delay in the region of 30-70%, and intake data show people self-stopping at substantially smaller volumes. ⚠ Two problems recur in equal measure: the plate is too big, and pushing through it brings nausea or vomiting within the hour. ★ What works is unglamorous — ask for a box at the start, split a main, order an appetizer as the meal, eat the protein first, and go slowly enough to notice the signal before you pass it. ⛔ One safety note that belongs here rather than in a footnote: cohort data comparing GLP-1 users against another weight drug found substantially higher rates of pancreatitis, bowel obstruction and gastroparesis. Those are uncommon in absolute terms, and repeatedly eating to the point of vomiting is not a good way to test your luck against them.

Source thread ↗PMID 28941314PMID 33567185PMID 37796527

Q5.The drug killed my appetite before an event I'd looked forward to.

★ This is a real loss and it deserves naming rather than reframing. The same mechanism that makes the drug work — quieter food noise, blunted reward from eating — does not switch off for the meal you had been anticipating for months. ⚠ The research supports the experience: work on food-cue reactivity describes those intrusive food-focused thoughts, and an analysis of more than 5,000 user posts found almost everyone describing weaker cravings and less satisfaction from both food and drink. ⛔ What the trials did NOT do is measure this. The STEP patient-reported outcomes captured better physical functioning and quality of life tied to weight, and never separately quantified the loss of pleasure in eating. So the honest answer is that your experience is common, coherent with the mechanism, and simply unstudied. ★ Practically: eat the thing you care about first, early, and in a small portion, while there is still room.

Source thread ↗PMID 38004203PMID 38928616PMID 38698650

Q6.A week of holiday eating and the scale barely moved — really?

★ Really, and it is not a broken scale. Energy-balance arithmetic on a 1,000-1,500 calorie daily surplus over five to seven days predicts roughly 1.4 to 3 lb of genuine fat gain, and what people report instead is 0 to 2 lb that disappears within a week — which is mostly food volume, fluid and sodium rather than fat. ⚠ The maintenance trials support the underlying picture: in SURMOUNT-4 the continued-tirzepatide arm lost a further 5.5% across the maintenance phase despite ordinary imperfect eating, and in STEP-4 those who stayed on semaglutide were still losing at week 68, holidays and travel included. ★ The mechanism is that appetite suppression does not switch off for a vacation; intake in the days after a blowout tends to fall on its own without anyone deciding it should. ⛔ Which is exactly why the compensatory restriction people impose on return is usually unnecessary.

Source thread ↗PMID 38078870PMID 33755728

Q7.Is heavy drinking at a party actually risky on this?

⛔ This is the genuine safety answer on the page, because it stacks two pancreatitis triggers on the same night. Cohort data comparing GLP-1 users for weight loss against another weight drug found a roughly nine-fold higher rate of pancreatitis, along with raised bowel obstruction and gastroparesis. Heavy alcohol intake is independently among the leading causes of acute pancreatitis. Together they are not additive in a reassuring way. ⚠ The symptom to know before the night rather than after: severe upper abdominal pain boring through to the back, with or without vomiting, needs same-day care. ★ There is a countervailing and slightly odd fact — a randomized trial found semaglutide reduced both heavy-drinking days and the amount consumed, so many people find they drink far less without having decided to. ⛔ If that has not happened to you, this is worth deliberate limits rather than trusting the effect to arrive.

Source thread ↗PMID 37796527PMID 39937469PMID 38928616PMID 38017205

Q8.How do I handle comments and pressure from family?

⚠ Two dynamics show up every year and they need different responses. One is relatives reading a small plate as a rejection of the family and its cooking. The other is relatives reading weight loss itself as illness, or as some kind of moral test you are failing or passing. ★ The trial data are relevant here and are more nuanced than they get credited for: pooled patient-reported outcomes across the STEP program found people moving more easily and rating their weight-related quality of life higher, with larger effects at larger weight losses — and a separate trial found parallel gains in body image and self-perceived health. Improvement on average is not improvement for everyone, and the social side of this is where the exceptions cluster. ★ What people report working is boring and effective: take a small portion of everything rather than declining dishes, praise the cooking specifically, and answer questions about the drug with one flat sentence and a change of subject. ⛔ You are not obliged to disclose a prescription at a dinner table.

Source thread ↗PMID 38698650PMID 36905345

Q9.Should I skip a dose so I can enjoy a cruise?

⚠ Understandable, and it costs more than people expect. The withdrawal trials show what sustained discontinuation does: in STEP-4, switching to placebo at week 20 meant 6.9% regained by week 68 while continuing meant a further 7.9% lost; in SURMOUNT-4, the placebo switch regained about 14% while continuing lost another 5.5%; and a year off semaglutide returned roughly two-thirds of prior loss. ★ One skipped weekly dose does not reproduce any of that — it is not the same event, and treating it as catastrophic is wrong. ⛔ But it does start dialing the appetite effect back down, and the practical risk is what follows: a week of restored appetite in an all-you-can-eat environment, then re-titration nausea on return. ★ The alternative most people land on is keeping the dose and choosing what to spend capacity on. You will eat less either way; the choice is whether you also spend the week feeling sick.

Source thread ↗PMID 33755728PMID 38078870PMID 35441470

Q10.How do I restart after the holidays?

★ Expect one to three weeks, not months — and the trial curves back that up rather than just sounding encouraging. STEP-5 followed people to two years and kept producing small losses past month 12, approaching about 15.2% below baseline at 104 weeks, with real-world holidays sitting inside that window. Nothing about the average trajectory suggests a December undoes a year. ⚠ The most effective restart is structure rather than restriction: SURMOUNT-3 showed that adding intensive lifestyle support after a run-in produced 18.4% additional loss on tirzepatide against 2.5% regained on placebo. ⛔ What does not work is compensating with severe restriction, which on a drug that already suppresses appetite pushes protein far too low and makes the next weeks harder. ★ Go back to the protein target, the usual meal structure and the injection schedule, and let the curve do what it did before.

Source thread ↗PMID 36216945PMID 37840095PMID 37836485

References

  1. 1.Yanovski JA, Yanovski SZ, Sovik KN, et al A prospective study of holiday weight gain N Engl J Med. 2000. PMID: 10727591.
  2. 2.Helander EE, Wansink B, Chieh A Weight Gain over the Holidays in Three Countries N Engl J Med. 2016. PMID: 27653588.
  3. 3.Abdulan IM, Popescu G, Mastaleru A, et al Winter Holidays and Their Impact on Eating Behavior - A Systematic Review Nutrients. 2023. PMID: 37836485.
  4. 4.Wilding JPH, Batterham RL, Calanna S, et al Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  5. 5.Jastreboff AM, Aronne LJ, Ahmad NN, et al Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
  6. 6.Rubino D, Abrahamsson N, Davies M, et al Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial JAMA. 2021. PMID: 33755728.
  7. 7.Aronne LJ, Sattar N, Horn DB, et al Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. 2024. PMID: 38078870.
  8. 8.Wilding JPH, Batterham RL, Davies M, et al Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes Obes Metab. 2022. PMID: 35441470.
  9. 9.Garvey WT, Batterham RL, Bhatta M, et al Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Nat Med. 2022. PMID: 36216945.
  10. 10.Wadden TA, Chao AM, Machineni S, et al Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial Nat Med. 2023. PMID: 37840095.
  11. 11.Hjerpsted JB, Flint A, Brooks A, et al Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity Diabetes Obes Metab. 2018. PMID: 28941314.
  12. 12.Maselli DB, Camilleri M Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity Adv Exp Med Biol. 2021. PMID: 32077010.
  13. 13.Sodhi M, Rezaeianzadeh R, Kezouh A, et al Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss JAMA. 2023. PMID: 37796527.
  14. 14.Hendershot CS, Bremmer MP, Paladino MB, et al Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial JAMA Psychiatry. 2025. PMID: 39937469.
  15. 15.Quddos F, Hubshman Z, Tegge A, et al Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity Sci Rep. 2023. PMID: 38017205.
  16. 16.Arillotta D, Floresta G, Papanti Pelletier GD, et al Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach Brain Sci. 2024. PMID: 38928616.
  17. 17.Hayashi D, Edwards C, Emond JA, et al What Is Food Noise? A Conceptual Model of Food Cue Reactivity Nutrients. 2023. PMID: 38004203.
  18. 18.Rubino D, Bjorner JB, Rathor N, et al Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials Diabetes Obes Metab. 2024. PMID: 38698650.
  19. 19.Kolotkin RL, Jeppesen OK, Baker-Knight J, et al Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial Clin Obes. 2023. PMID: 36905345.

Questions are paraphrased from public forum threads and linked to their source where one was recorded. Answers summarize published trial data and FDA labeling. This is not medical advice, and no part of it replaces the judgment of whoever prescribes for you.